Johnson & Johnson (NYSE:JNJ) Shares Up 0.1%

Shares of Johnson & Johnson (NYSE:JNJGet Free Report) traded up 0.1% during trading on Wednesday . The company traded as high as $152.60 and last traded at $151.54. 1,043,039 shares were traded during trading, a decline of 86% from the average session volume of 7,335,615 shares. The stock had previously closed at $151.38.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on JNJ shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, May 6th. Royal Bank of Canada decreased their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.86.

Read Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Up 0.9 %

The firm has a market cap of $367.50 billion, a price-to-earnings ratio of 9.52, a P/E/G ratio of 2.49 and a beta of 0.55. The firm’s 50-day moving average is $152.63 and its 200-day moving average is $154.99. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same period last year, the firm earned $2.68 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s payout ratio is presently 29.68%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently made changes to their positions in JNJ. Mount Yale Investment Advisors LLC increased its position in Johnson & Johnson by 4.9% in the first quarter. Mount Yale Investment Advisors LLC now owns 22,051 shares of the company’s stock worth $3,488,000 after buying an additional 1,033 shares during the last quarter. Beaird Harris Wealth Management LLC increased its holdings in Johnson & Johnson by 19.1% in the 1st quarter. Beaird Harris Wealth Management LLC now owns 2,778 shares of the company’s stock worth $439,000 after acquiring an additional 446 shares during the last quarter. Manhattan West Asset Management LLC lifted its holdings in Johnson & Johnson by 27.9% during the first quarter. Manhattan West Asset Management LLC now owns 13,609 shares of the company’s stock valued at $2,153,000 after purchasing an additional 2,967 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Johnson & Johnson by 16.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after purchasing an additional 3,139,499 shares during the period. Finally, Kestra Advisory Services LLC increased its stake in shares of Johnson & Johnson by 7.1% in the first quarter. Kestra Advisory Services LLC now owns 351,902 shares of the company’s stock worth $55,667,000 after purchasing an additional 23,297 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Articles

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.